The "Increasing Transparency in the Management of Pharmaceutical Product Quality and NHI Prices Forum" organized by BNHI and FDA was held between 9:00 and 12:40 on April 25, 2012 at the 18th-floor hall in the BNHI building. The forum was hosted by DOH
Chief Secretary Szu-Hai Lin along with representatives from consumer groups, pharmaceutical companies, and scholars totaling over 150 participants.
The BNHI has been committed to balancing NHI finances and has been conducting drug price surveys and adjustments to reduce the gap between NHI and market prices. This brought pharmaceutical product quality once again to the foreground. The theme of the
forum is pharmaceutical product quality management policies. The FDA would report on "Quality control of drugs on the market" and "current management of GMP certified manufacturers of western medicine in Taiwan." In response to the requirement by the Second
Generation National Health Insurance to disclose information and increase transparency in decision making, the BNHI has prepared a report on "the moral and avoiding of conflicts of interest in NHI drug management." Special guests, including Consumers' Foundation,
Chinese Taipei (CFCT) director Tian-ren Xie, National Taiwan University Associate professor Dr. Ming-chin Yang, and representatives from 8 major pharmaceutical associations and pharmaceutical companies, would offer their views regarding these issues. Their
suggestions would serve as a reference point for management improvement and future policy making and revising. The BNHI would remain committed to improving administrative transparency.
The forum brings together scholars and experts from the government, industry, and academia to exchange ideas on how to increase transparency in the management of pharmaceutical product quality and NHI prices. It is expected that the forum would yield much